佐谷　秀行 （サヤ　ヒデユキ）

Saya, Hideyuki

写真a

所属（所属キャンパス）

医学部 （三田）

職名

名誉教授

外部リンク
このページの先頭へ▲

プロフィール 【 表示 ／ 非表示 】

  • 1981年に神戸大学医学部を卒業し、1983年まで脳神経外科研修医。その後、神戸大学大学院医学研究科に入学し1987年に博士号（医学）を取得。その後UCSFのポスドクを経て、1988年よりMD Anderson Cancer CenterのAssistant Professor（Neuro-Oncology）。1994年から2006年まで熊本大学医学部教授（腫瘍医学講座）、2007年より慶應義塾大学医学部教授。2016年より慶應義塾大学病院副院長、臨床研究推進センター長。

このページの先頭へ▲

その他の所属・職名 【 表示 ／ 非表示 】

  • 医学部, 教授

このページの先頭へ▲
 

論文 【 表示 ／ 非表示 】

  • 2-Nitroimidazoles induce mitochondrial stress and ferroptosis in glioma stem cells residing in a hypoxic niche

    Koike N., Kota R., Naito Y., Hayakawa N., Matsuura T., Hishiki T., Onishi N., Fukada J., Suematsu M., Shigematsu N., Saya H., Sampetrean O.

    Communications Biology （Communications Biology）  3 （ 1 ）  2020年12月

    　概要を見る

    © 2020, The Author(s). Under hypoxic conditions, nitroimidazoles can replace oxygen as electron acceptors, thereby enhancing the effects of radiation on malignant cells. These compounds also accumulate in hypoxic cells, where they can act as cytotoxins or imaging agents. However, whether these effects apply to cancer stem cells has not been sufficiently explored. Here we show that the 2-nitroimidazole doranidazole potentiates radiation-induced DNA damage in hypoxic glioma stem cells (GSCs) and confers a significant survival benefit in mice harboring GSC-derived tumors in radiotherapy settings. Furthermore, doranidazole and misonidazole, but not metronidazole, manifested radiation-independent cytotoxicity for hypoxic GSCs that was mediated by ferroptosis induced partially through blockade of mitochondrial complexes I and II and resultant metabolic alterations in oxidative stress responses. Doranidazole also limited the growth of GSC-derived subcutaneous tumors and that of tumors in orthotopic brain slices. Our results thus reveal the theranostic potential of 2-nitroimidazoles as ferroptosis inducers that enable targeting GSCs in their hypoxic niche.

  • Phosphorylation of the Anaphase Promoting Complex activator FZR1/CDH1 is required for Meiosis II entry in mouse male germ cell

    Tanno N., Kuninaka S., Fujimura S., Takemoto K., Okamura K., Takeda N., Araki K., Araki M., Saya H., Ishiguro K.i.

    Scientific Reports （Scientific Reports）  10 （ 1 ）  2020年12月

    　概要を見る

    © 2020, The Author(s). FZR1/CDH1 is an activator of Anaphase promoting complex/Cyclosome (APC/C), best known for its role as E3 ubiquitin ligase that drives the cell cycle. APC/C activity is regulated by CDK-mediated phosphorylation of FZR1 during mitotic cell cycle. Although the critical role of FZR1 phosphorylation has been shown mainly in yeast and in vitro cell culture studies, its biological significance in mammalian tissues in vivo remained elusive. Here, we examined the in vivo role of FZR1 phosphorylation using a mouse model, in which non-phosphorylatable substitutions were introduced in the putative CDK-phosphorylation sites of FZR1. Although ablation of FZR1 phosphorylation did not show substantial consequences in mouse somatic tissues, it led to severe testicular defects resulting in male infertility. In the absence of FZR1 phosphorylation, male juvenile germ cells entered meiosis normally but failed to enter meiosis II or form differentiated spermatids. In aged testis, male mutant germ cells were overall abolished, showing Sertoli cell-only phenotype. In contrast, female mutants showed apparently normal progression of meiosis. The present study demonstrated that phosphorylation of FZR1 is required for temporal regulation of APC/C activity at meiosis II entry, and for maintenance of spermatogonia, which raised an insight into the sexual dimorphism of FZR1-regulation in germ cells.

  • Downregulation of the CCL2/CCR2 and CXCL10/CXCR3 axes contributes to antitumor effects in a mouse model of malignant glioma

    Shono K., Yamaguchi I., Mizobuchi Y., Kagusa H., Sumi A., Fujihara T., Nakajima K., Kitazato K.T., Matsuzaki K., Saya H., Takagi Y.

    Scientific Reports （Scientific Reports）  10 （ 1 ）  2020年12月

    　概要を見る

    © 2020, The Author(s). Glioblastoma multiforme involves glioma stem cells (GSCs) that are resistant to various therapeutic approaches. Here, we studied the importance of paracrine signaling in the glioma microenvironment by focusing on the celecoxib-mediated role of chemokines C–C motif ligand 2 (CCL2), C-X-C ligand 10 (CXCL10), and their receptors, CCR2 and CXCR3, in GSCs and a GSC-bearing malignant glioma model. C57BL/6 mice were injected with orthotopic GSCs intracranially and divided into groups administered either 10 or 30 mg/kg celecoxib, or saline to examine the antitumor effects associated with chemokine expression. In GSCs, we analyzed cell viability and expression of chemokines and their receptors in the presence/absence of celecoxib. In the malignant glioma model, celecoxib exhibited antitumor effects in a dose dependent manner and decreased protein and mRNA levels of Ccl2 and CxcL10 and Cxcr3 but not of Ccr2. CCL2 and CXCL10 co-localized with Nestin+ stem cells, CD16+ or CD163+ macrophages and Iba-1+ microglia. In GSCs, celecoxib inhibited Ccl2 and Cxcr3 expression in a nuclear factor-kappa B-dependent manner but not Ccr2 and CxcL10. Moreover, Ccl2 silencing resulted in decreased GSC viability. These results suggest that celecoxib-mediated regulation of the CCL2/CCR2 and CXCL10/ CXCR3 axes may partially contribute to glioma-specific antitumor effects.

  • Molecular and cellular mechanisms underlying brain metastasis of breast cancer

    Hosonaga M., Saya H., Arima Y.

    Cancer and Metastasis Reviews （Cancer and Metastasis Reviews）  39 （ 3 ） 711 - 720 2020年09月

    ISSN  01677659

    　概要を見る

    © 2020, The Author(s). Metastasis of cancer cells to the brain occurs frequently in patients with certain subtypes of breast cancer. In particular, patients with HER2-positive or triple-negative breast cancer are at high risk for the development of brain metastases. Despite recent advances in the treatment of primary breast tumors, the prognosis of breast cancer patients with brain metastases remains poor. A better understanding of the molecular and cellular mechanisms underlying brain metastasis might be expected to lead to improvements in the overall survival rate for these patients. Recent studies have revealed complex interactions between metastatic cancer cells and their microenvironment in the brain. Such interactions result in the activation of various signaling pathways related to metastasis in both cancer cells and cells of the microenvironment including astrocytes and microglia. In this review, we focus on such interactions and on their role both in the metastatic process and as potential targets for therapeutic intervention.

  • Targeting of cancer stem cells by differentiation therapy

    Arima Y., Nobusue H., Saya H.

    Cancer Science （Cancer Science）  111 （ 8 ） 2689 - 2695 2020年08月

    ISSN  13479032

    　概要を見る

    © 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. Chemoresistance is a hallmark of cancer stem cells (CSCs). To develop novel therapeutic strategies that target CSCs, we established osteosarcoma-initiating (OSi) cells by introducing the c-Myc gene into bone marrow stromal cells derived from Ink4a/Arf KO mice. These OSi cells include bipotent committed cells (similar to osteochondral progenitor cells) with a high tumorigenic activity as well as tripotent cells (similar to mesenchymal stem cells) of low tumorigenicity. We recently showed that the tripotent OSi cells are highly resistant to chemotherapeutic agents, and that depolymerization of the actin cytoskeleton in these cells induces their terminal adipocyte differentiation and suppresses their tumorigenicity. We here provide an overview of modulation of actin cytoskeleton dynamics associated with terminal adipocyte differentiation in osteosarcoma as well as discuss the prospects for new therapeutic strategies that target chemoresistant CSCs by inducing their differentiation.

全件表示 >>

このページの先頭へ▲

KOARA（リポジトリ）収録論文等 【 表示 ／ 非表示 】

全件表示 >>

このページの先頭へ▲

競争的研究費の研究課題 【 表示 ／ 非表示 】

  • メチオニン代謝を基盤としたがん治療抵抗性機構の解明と新規治療標的の同定

    2021年07月
    -
    2023年03月

    文部科学省・日本学術振興会, 科学研究費助成事業, 佐谷 秀行, 挑戦的研究（萌芽）, 補助金,  研究代表者

  • がん関連線維芽細胞誘導分子機構の解明とその阻害に基づく腫瘍微小環境制御

    2020年04月
    -
    2023年03月

    文部科学省・日本学術振興会, 科学研究費助成事業, 佐谷 秀行, 基盤研究(A), 補助金,  研究代表者

  • 癌細胞シグナル活性化因子14-3-3ζを標的とした新規膵臓癌治療薬の開発

    2019年06月
    -
    2021年03月

    文部科学省・日本学術振興会, 科学研究費助成事業, 佐谷　秀行, 挑戦的研究（萌芽), 補助金,  研究代表者

  • 転写調節因子MKL1によるがん関連線維芽細胞誘導機構の解明とがん治療への応用

    2017年04月
    -
    2020年03月

    文部科学省・日本学術振興会, 科学研究費助成事業, 佐谷　秀行, 基盤研究(A), 補助金,  研究代表者

このページの先頭へ▲
 

担当授業科目 【 表示 ／ 非表示 】

  • メディカル・プロフェッショナリズムⅢ

    2023年度

  • メディカル・プロフェッショナリズムⅢ

    2022年度

  • ＭＣＢ

    2022年度

  • 先端医療技術

    2022年度

  • 先端医科学

    2022年度

全件表示 >>

このページの先頭へ▲